We report findings in phase II of a pilot study of cystic fibrosis (CF) carrier screening/testing by mutation analysis. Phase I has been reported elsewhere. Eligible participants in phase II (n = 815) were students (15 to 17 years of age) in public high schools. An educational component (exchange of information and discussion about common genetic disorders including CF) preceded, by one week or more, voluntary participation in the screening component which required a blood sample.
riers of these alleles were found. Carriers had positive views of the education and testing experiences. Persons identified as 'non-carriers' were also surveyed (n= 135, response rate 41%). As in phase I, the majority (83%) again understood that a negative DNA test had not excluded them from possible carrier status. Students who participated in the informational component but were not screened served here as controls in the follow up survey (n = 208, response rate 53%). Their views were similar to those of the screened non-carriers, and similar also to those held by students, adults, pregnant women, couples, and CF relatives in other communities. (J Med Genet 1993; 30:538-42) Cystic fibrosis (CF) is one of the most common of the severe autosomal recessive diseases affecting Caucasians.' The carrier frequency is about 1 in 25 among Europeans. Identification and characterisation of the cystic fibrosis transmembrane regulator (CFTR) gene,2 3 and of the most prevalent mutation associated with CF,4 has made carrier screening both a possibility and a subject of controversy.
There are reasons for and against CF carrier screening or testing at the present time. We distinguish here between genetic screening and testing. consent of parents, the school board, and the teachers.
UPTAKE
Students first attended an information session which covered basic genetic principles and relevant information about CF. Pamphlets describing CF, the project, and issues associated with carrier screening were given to each student. Participants in the screening component identified their ancestral origins (ethnic and geographical).
SAMPLE
Heparinised venous blood was drawn from the antecubital vein and, on the same day, DNA was phenol extracted from leucocytes. Screening took place at least one week after the information session; it was organised within curriculum time on school premises.
TEST RESULTS
A personal letter explaining the result of mutation analysis was sent to each participant. One or two weeks after the results were sent, carriers were called, counselled further if the letter explaining the significance of carrier status needed clarification, and asked questions relevant to the project (see below). Counselling, with mutation analysis if desired, was offered to family members.
ANALYTICAL METHODS
DNA was amplified by the polymerase chain reaction (PCR), and analysed for the mutations AF508, G551D, G542X, W1282X, and -549-.
EVALUATION
This component was carried out after the results of the test had been returned to the participants. We distributed a questionnaire to all participants, both carriers and non-carriers. A separate questionnaire was also distributed to persons who had not participated in the screening phase (controls) to evaluate their attitudes and reasons for non-participation. Controls were selected to match the participants according to school attended, gender, and age. Knowledge and attitudes among the nonscreened controls (n = 208) were compared with screened non-carriers (n = 135) (table 2) . Attitudes in the two groups were very similar. Among the screened non-carrier respondents, only one expressed disapproval of pre-pregnancy carrier testing, and among the controls Table 2 Comparison of knowledge in screened non-carriers and non-screened controls.
Screened non-carriers (n = 135) Non-screened controls (n = 208) Yes (%) Yes (%) Participation rates in the screening components of phases I and II in the project were low (< 43%) compared to about 70% in the corresponding Tay-Sachs and P thalassaemia screening programmes in Montreal. The reasons given for non-participation here were objection to a blood test and possible AIDS infection, failure to bring the signed permission form (a requisite for the pilot study), and lack of interest. Nevertheless these factors clearly did not imply disapproval of screening (table  2) . When the blood test was replaced by a buccal rinse in phase III, the participation rose to 70%. 31 The frequency of detectable CF mutation has reached an 'acceptable' level in two populationsl0 11 
